Recent additions to our Life Sciences Notes blog include a podcast featuring Veronica Roberts - who leads our global foreign direct investment group and was closely involved in the introduction of the UK’s National Security and Investment (NSI) regime – on the impact of the regime on deals in the pharmaceuticals and healthcare sector, focusing on the NSI review process. Additionally, our Intellectual Property experts examine the impact of the EU’s new Unitary Patent Court since its launch, and look at the data on Unitary Patent applications.
Other updates include a review of the UK Competition Appeal Tribunal’s decision to dismiss appeals against the CMA’s findings of abuse of dominance relating to excessive pricing of liothyronine tablets. Finally, our dispute resolution and commercial contracts teams consider best practice and risk management strategies when engaging with Contract Research Organisations (CROs), offering practical tips on how companies can navigate these complex agreements.
Featured articles can be accessed via the links below.
- The UK National Security and Investment regime: spotlight on pharma M&A
- Live figures from the European Patent Office show healthy appetite for Unitary Patents
- The UPC and unitary patents – six weeks in
- CAT upholds CMA excessive pricing decision in liothyronine tablets case
- Navigating Contract Research Organisation Agreements: A legal perspective
Key contacts
Laura Orlando
Italy Managing Partner, Joint Global Head of Intellectual Property, EMEA Co-Head of Life Sciences, Milan
Disclaimer
The articles published on this website, current at the dates of publication set out above, are for reference purposes only. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action.